Opus completes cohort 1 enrollment

Gene therapy for rare retinal disease is one of those fields where the timeline matters almost as much as the data. These are tiny patient populations, the diseases progress slowly but relentlessly, and every enrollment milestone tells you whether a program is actually moving or just sitting in slide decks. That is why Opus Genetics’ update matters. On May 7, the company said it had completed enrollment in cohort 1 of its phase 1/2 OPGx-BEST1 trial and now expects 3-month topline data in September 2026. ### What is OPGx-BEST1? OPGx-BEST1 is an AAV-based gene therapy aimed at diseases caused by mutations in the BEST1 gene. Those mutations can drive different inherited retinal disorders, including autosomal recessive bestrophinopathy and Best vitelliform macular dystrophy. The basic idea is simple — deliver a working copy of BEST1 to retinal pigment epithelium cells through a one-time subretinal injection and try to restore function before damage becomes irreversible. ### What changed this week? The concrete news is enrollment. Cohort 1 is now fully enrolled in the ongoing phase 1/2 study, which means the clock starts on a cleaner near-term catalyst: 3-month data for the whole cohort in September 2026. For a small clinical-stage biotech, that matters because investors and clinicians can finally anchor expectations to a specific readout instead of a vague “mid-year” or “later this year” window. ### Had Opus shown anything before this? Yes — but only in a very early way. Back on February 27, Opus shared initial BEST1 data from a sentinel participant at the Macula Society meeting. The company said the treated patient had no ocular inflammation, no treatment-related adverse events, and no dose-limiting toxicities and a central subfield thickness in the treated eye. That is encouraging, but it is still one patient. ### Why does cohort enrollment matter so much? Because in rare-disease gene therapy, logistics are half the battle. Finding genetically confirmed patients, screening them, and getting them to a surgical center for subretinal dosing is hard. Finishing a cohort does not prove the therapy works, but it does prove the trial is operationally real. Basically, it turns a concept into a schedule. ### What about the ARVO update? Opus paired the BEST1 enrollment news with presentations at ARVO 2026 in Denver, held May 3–7. The headline there was broader pipeline momentum, especially OPGx-LCA5. The company said pediatric LCA5 data suggest restoration of cone-mediated daytime vision, with some measures of retinal sensitivity improving into normal ranges by six months in treated children with severe early-onset disease. ### Does that change care right now? Not really. These are still early-stage datasets, and they are coming from company presentations rather than a mature registrational package. No one should read this as an immediate change in standard practice. But it does matter for referral behavior, genetic testing, and registry building — especially for centers that want eligible patients identified before these programs get further along. ### Why is Opus getting extra attention now? Because the company has been stacking milestones. It recently said OPGx-LCA5 was accepted into the FDA’s Rare Disease Evidence Principles program, and in April it announced a long-term financing deal with Oberland Capital to help fund development and manufacturing across the retinal pipeline. That does not remove clinical risk, but it gives the company a clearer path to keep these programs moving. ### Bottom line? This is not a practice-changing breakthrough yet. It is a progress marker — but a meaningful one. Opus now has a defined September 2026 data catalyst for BEST1, and its ARVO presentations suggest the company is trying to build a multi-program inherited-retinal-disease story rather than rely on a single shot on goal.